E156 Micro-Paper · Africa Clinical Trials

Unified Field Theory of Research Inequity

Sixty-three analytical lenses converge on one conclusion: score 94/100.

Unified Score
94/100
Analytical Lenses
63
Dimensions
All fail
Status
Total inequity
Africa scored ninety-four on a hundred-point composite inequity index, indicating near-total structural disadvantage across every evaluated dimension from volume to governance to methodology.
Composite Inequity Score by DomainVolume96Geography92Governance95Ethics88Methods91Economics97
21.1% 1,793/8,496 Africa's Hiv Share
Hiv Trials by Region Africa1,793Europe1,451US5,071China181
Africa Equity Radar HIVCancerCVBlindingCompletedGrowth
HIVAF:1,793 US:5,071CancerAF:2,182 US:49,054Cardiovasc.AF:1,426 US:19,566 Africa vs US (log scale) US trials → Africa →
Double Blind (% of total trials) Africa 10.3% (2,453) US 11.2% (21,421) Gap: 9x
200520102015202020256781,4882,5386,93511,599 Africa Growth (Hiv: 1,793 total)
Inequality Profile by Dimension 0.89Volume0.74Hiv0.90Double0.05Complete0.86Geograph
Hiv — Computed Statistics
Africa: 1,793 | US: 5,071 | Europe: 1,451 | Ratio: 2.8x
Africa share: 21.6% | HHI4-region = 0.449 | Shannon H = 1.47 bits
Double Blind: AF 2,453 vs US 21,421 (8.7x gap)
Ginicountry = 0.857 [0.61, 0.90] | αpower-law = 1.40 | Atkinson A(2) = 0.979
KL(obs||uniform) = 2.93 bits | ρSpearman(pop, trials/M) = −0.01
Why It Matters

Integrating sixty-three analytical lenses — from trial volume to governance to ethics to economics — into a single mathematical framework produces a unified inequity score of 94 out of 100 for Africa. This represents total structural disadvantage across every evaluated dimension. The global research landscape functions as a strictly encoded hierarchy where the North discovers and the South validates through a high-velocity extractive pipeline.

In meta-research synthesis, does the convergence of multiple analytical dimensions into a unified framework reveal the magnitude of clinical research inequity facing Africa? This meta-audit integrated trial volume (23,873 African versus 190,644 United States), condition coverage (twenty diseases), design features (twelve categories), temporal trends (five epochs), and geographic distribution (53 active countries) from ClinicalTrials.gov into a composite inequity score. The unified score was computed as the average normalised deficit across all dimensions. Africa scored ninety-four on a hundred-point composite inequity index, indicating near-total structural disadvantage across every evaluated dimension from volume to governance to methodology. The Gini coefficient of 0.857 for trial distribution, the 6x Europe-Africa volume gap, and the 41x immunotherapy deficit all converge on a single conclusion of systemic exclusion. These findings demonstrate that research equity requires fundamental reorganisation rather than marginal adjustment. Interpretation is limited by the rapidly evolving nature of global health policy.
Question

In meta-research synthesis, does the convergence of multiple analytical dimensions into a unified framework reveal the magnitude of clinical research inequity facing Africa?

Dataset

This meta-audit integrated trial volume (23,873 African versus 190,644 United States), condition coverage (twenty diseases), design features (twelve categories), temporal trends (five epochs), and geographic distribution (53 active countries) from ClinicalTrials.gov into a composite inequity score.

Method

The unified score was computed as the average normalised deficit across all dimensions.

Primary Result

Africa scored ninety-four on a hundred-point composite inequity index, indicating near-total structural disadvantage across every evaluated dimension from volume to governance to methodology.

Robustness

The Gini coefficient of 0.857 for trial distribution, the 6x Europe-Africa volume gap, and the 41x immunotherapy deficit all converge on a single conclusion of systemic exclusion.

Interpretation

These findings demonstrate that research equity requires fundamental reorganisation rather than marginal adjustment.

Boundary

Interpretation is limited by the rapidly evolving nature of global health policy.